Treatment of hepatitis delta chronic infection: HBs antigen quantification may help monitoring, and HBs antigen seroconversion could be the ideal 'end' point of treatment

Journal of Clinical Virology

Volumn 55, Issue 1, 2012, Pages 83-84

  Brichler, Ségolène ^a   Setshedi, Mashiko ^b   Renou, Christophe ^c  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Hyeres Hospital   (France)

Author keywords

Adefovir; HBsAg quantification; HDV RNA quantification; Hepatitis D virus; Peg interferon alpha

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA; VIRUS RNA;

ADULT; CASE REPORT; DELTA AGENT HEPATITIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS DELTA VIRUS; HUMAN; LETTER; MALE; MONITORING; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS D, CHRONIC; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 84865170161     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.05.015     Document Type: Letter

References (13)

1. Romeo R., Colombo M. Treatment of chronic hepatitis delta: mission impossible?. Gastroenterology 2011, 141(6):2268-2271.
2. Hoofnagle J.H., di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 1997, 336(5):347-356.
3. Castelnau C., Le Gal F., Ripault M.P., Gordien E., Martinot-Peignoux M., Boyer N., et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44(3):728-735.
4. Niro G.A., Ciancio A., Gaeta G.B., Smedile A., Marrone A., Olivero A., et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006, 44(3):713-720.
5. Gunsar F., Akarca U.S., Ersoz G., Kobak A.C., Karasu Z., Yuce G., et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005, 10(6):721-726.
6. Yurdaydin C., Bozkaya H., Onder F.O., Senturk H., Karaaslan H., Akdogan M., et al. Treatment of chronic delta hepatitis with lamivudine vs. lamivudine+interferon vs. interferon. J Viral Hepatitis 2008, 15(4):314-321.
7. Wedemeyer H., Yurdaydin C., Dalekos G.N., Erhardt A., Cakaloglu Y., Degertekin H., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011, 364(4):322-331.
8. Le Gal F., Gordien E., Affolabi D., Hanslik T., Alloui C., Deny P., et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005, 43(5):2363-2369.
9. Manesis E.K., Schina M., Le Gal F., Agelopoulou O., Papaioannou C., Kalligeros C., et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 2007, 12(3):381-388.
10. Deguchi M., Yamashita N., Kagita M., Asari S., Iwatani Y., Tsuchida T., et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004, 115(2):217-222.
11. Tangkijvanich P., Komolmit P., Mahachai V., Sa-nguanmoo P., Theamboonlers A., Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009, 46:117-123.
12. Moucari R., Korevaar A., Lada O., Martinot-Peignoux M., Boyer N., Mackiewicz V., et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009, 50:1084-1092.
13. Zachou K., Yurdaydin C., Drebber U., Dalekos G.N., Erhardt A., Cakaloglu Y., et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010, 30(3):430-437.